Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation

European Journal of Heart Failure - Tập 14 Số 8 - Trang 939-945 - 2012
Simon Biner1,2, Robert J. Siegel3, Ted Feldman4, Asim Rafique3, Alfredo Trento3, Patrick L. Whitlow5, Jason H. Rogers6, Marc R. Moon7, Brian R. Lindman7, Alan Zajarías7, Donald D. Glower8, Saibal Kar3
1Cedars-Sinai Heart Institute, Los Angeles, CA 90048, USA
2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3Cedars Sinai Heart Institute, Los Angeles, CA 90048, USA.
4Evanston Hospital, Evanston, IL, USA
5The Cleveland Clinic, Cleveland, OH, USA
6University of California, Davis, Medical Center, Sacramento, CA, USA
7Washington University School of Medicine, Saint Louis, MO, USA
8Duke University Medical Center, Durham, NC USA

Tóm tắt

AimsTo evaluate the haemodynamic effect of acute procedural success (APS) after MitraClip therapy in patients with haemodynamic decompensation.Methods and resultsOf 107 patients, 79 achieved APS after MitraClip implantation. The increase in cardiac index (CI) was primarily detected in patients with a low baseline CI (2.0 ± 0.5 to 2.5 ± 5 L/min/m2, P < 0.001). There was a decrease in left ventricular end‐diastolic pressure (LVEDP) (20 ± 5 to 13 ± 5 mmHg, P = 0.002) and mean pulmonary capillary wedge pressure (PCWPm) (20 ± 4 to 16 ± 5 mmHg, P = 0.001) in patients with values >15 mmHg at baseline, and a decrease in mean pulmonary artery systolic (PAPm) (36 ± 4 to 29 ± 7 mmHg P = 0.003) in those with values >30 mmHg before the MitraClip procedure. Patients with decompensation compared with patients with compensation experienced significant reduction in LVEDP (–8.3 ± 11.9 mmHg vs. –0.2 ± 4.5 mmHg, P = 0.009), a reduction in PCWPm (–3.5 ± 5.6 mmHg vs. 1.9 ± 4.7 mmHg, P < 0.001), and a reduction in PAPm (–8 ± 9 mmHg vs. 3 ± 6 mmHg, P < 0.001).ConclusionThe favourable haemodynamic effects of MitraClip therapy on CI were primarily detected in patients with low CI before the procedure, and improvements in left‐sided filling pressure and PAP were primarily seen in those with elevated values at baseline.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa1009355

10.1093/eurjhf/hfr029

10.1093/eurjhf/hfr141

10.1016/j.jacc.2011.06.061

10.1016/j.jacc.2010.11.043

10.1136/heartjnl-2011-300705

Bonow RO, 2008, focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, J Am Coll Cardiol 2008, 52, e1

10.1093/eurheartj/ehm095

10.1161/01.CIR.99.3.400

10.1016/j.jtcvs.2011.08.030

10.1016/j.jacc.2005.07.065

10.1016/j.jacc.2010.08.116

10.1016/S0894-7317(03)00335-3

10.1016/0002-9149(71)90436-X

Kasper DL, 2005, Harrison's Principles of Internal Medicine

10.1152/physrev.1993.73.2.413

10.1016/j.jacc.2010.03.077

10.1093/eurheartj/ehm001

10.1016/j.jacc.2007.09.046

Thông tin
Thông tin xuất bản

European Journal of Heart Failure

Tập 14 Số 8

939-945

Thông tin tác giả